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Enhancing anticancer cytotoxicity through
bimodal drug delivery from ultrasmall Zr MOF
nanoparticles†
Isabel Aba´nades La´zaro, Sandra Aba´nades La´zaro and Ross S. Forgan *
Dual delivery of dichloroacetate and 5-fluorouracil from Zr MOFs
into cancer cells is found to enhance in vitro cytotoxicity. Tuning
particle size and, more significantly, surface chemistry, further
improves cytotoxicity by promoting caveolae-mediated endocytosis
and cytosolic cargo delivery.
Eﬀective cell internalisation and intracellular drug release are
vital characteristics of eﬀective nanoparticulate drug delivery
systems (DDSs).1 Nanoparticles are generally internalised through
active transport mechanisms such as endocytosis, however, if they
are small enough (o20 nm), nanoparticles can be internalised by
passive diﬀusion,2 enabling direct release of cargo into the
cytosol. Metal–organic frameworks (MOFs)3 – network structures
composed of metal clusters linked by multidentate organic
linkers with high porosity – offer the desirable combination of
large cargo payloads and tunable structural features,4 with zirconium
MOFs,5 which have requisite chemical stability for aqueous use,
emerging as promising potential DDSs.6
We have previously shown7 that 50–600 nm nanoparticles of
UiO-66, the zirconium 1,4-benzenedicarboxylate (bdc) MOF
with ideal formula [Zr6O4(OH)4(bdc)6]n, and its –Br, –NO2, and
–NH2 functionalised derivatives (L1–L4 in Fig. 1a), undergo HeLa
cancer cell internalisation primarily through clathrin-mediated
endocytosis, while isoreticular MOFs with more hydrophobic
extended linkers, such as 2,6-napthalenedicarboxylate (L5)
and 4,40-biphenyldicarboxylate (L6), are partially internalised
through caveolae-mediated endocytosis, with no induction of
cytotoxicity at concentrations up to 1 mg mL1.8 Similarly,
coating surfaces of UiO-66 nanoparticles with poly(ethylene
glycol) can promote caveolae-mediated uptake, allowing drug-
loaded MOFs to avoid the lysosomal degradation that is char-
acteristic of clathrin-mediated endocytosis and release their
cargo in the cytosol, thus enhancing therapeutic efficiency.9
This example utilised the anticancer metabolic molecule, dichloro-
acetic acid (DCA), as a modulator10 of UiO-66 solvothermal
synthesis, showing that it can be incorporated into UiO-66
nanoparticles at defects and on their surfaces (Fig. 1b), yielding
regular, well-dispersed, porous nanoparticles of around 100 nm
in size.9 Herein, we (i) investigate the DCA modulation protocol
across the isoreticular series of Zr MOFs illustrated in Fig. 1,
(ii) show that very small (ca. 20 nm), highly defective, DCA-
containing Zr MOFs can be prepared and loaded with a second
anticancer drug, and (iii) demonstrate enhanced in vitro cancer
cell cytoxicity of the dually active DDSs.
DCA is a pyruvate D-kinase inhibitor, which is over expressed
in cancerous cells, and its cytotoxic eﬀects on cancer cells depend
on eﬀective cytosolic release and mitochondrial localisation, thus
making it an ideal mechanistic probe molecule for cell uptake.11
To promote cytosolic release through passive diﬀusion, we have
tuned our previously reported synthetic conditions for DCA@Zr-L1
with the aim of obtaining smaller, DCA-loaded nanoparticles
(o20 nm) of the MOFs Zr-L1–Zr-L6 (ESI,† Section S2). Solvothermal
reaction of ZrOCl2 with 2.5 eq. of linker and 18.2 eq. of dichloro-
acetic acid yields solids whose powder X-ray diffraction (PXRD)
patterns (Fig. 2a) show Bragg peaks characteristic of the UiO-66
topology.5a When terephthalate linkers (L1 to L4) are used, the
diffraction patterns have broad, low intensity peaks, suggesting
Fig. 1 (a) Structures of linkers L1–L6 used in the preparation of all Zr-LX
MOFs. (b) Schematic of DCA@Zr-L1 with DCA capping Zr6 clusters to form
defects.
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small and defective particles, as a consequence of DCA attachment
to the Zr6 clusters in place of linkers.
12
Scanning electron microscopy (SEM) confirms that the
zirconium terephthalates form as 10–30 nm particles, which
are termed DCA@Zr-LXsmall to denote the small particle size;
DCA@Zr-L1small is shown as an exemplar in Fig. 2b. In contrast,
DCA@Zr-L5 nanoparticles have an unexpected ovoid morphology
(Fig. 2c) with diameters of 232 30 nm and lengths about 700 nm,
which, combined with additional reflections in the PXRD pattern,
suggests a defective, lower connectivity structure that has been
observed with acetic acid modulated analogues.13 DCA@Zr-L6
is composed of polycrystalline spherical nanoparticles of 196 
32 nm in size (Fig. S4, ESI†).
The terephthalate MOFs present type IV N2 adsorption and
desorption isotherms (77 K) with H2 hysteresis loops typical of
interconnected networks of pores with diﬀerent size and shape14
(illustrated for DCA@Zr-L1small in Fig. 2d). These suggest highly
defective structures, although some contribution of inter-particle
space should be considered. The BET surface areas are lower than
defect-free UiO-66 (1200 m2 g1),5a but the additional, defect-
induced mesoporosity results in extremely high pore volumes,
ranging from 0.8 to 1.2 cc g1. DCA@Zr-L5 (Fig. 2d) and
DCA@Zr-L6 (Fig. S7, ESI†) are also porous but do not exhibit
hysteresis, in concert with PXRD and SEM analysis that indicate
larger, less defective particles. The BET surface areas and pore
volumes are given in Table 1.
Nuclear magnetic resonance (NMR) spectra of acid-digested
samples confirm significant incorporation of DCA, while FT-IR
spectra show appearance of vibration bands characteristic
of DCA, but shifted to indicate its attachment at defect sites
(ESI,† Section S2). Thermogravimetric analysis (TGA) of the
DCA@MOFs shows significant mass loss events from 250–375 1C
compared to pristine materials (Fig. 2e and Fig. S11, ESI†),
allowing quantification of DCA content (Table 1). Analogous
terephthalate DCA@MOFs of larger size (ca. 100 nm) were also
synthesised as size controls following our previously reported
protocol.9 Full characterisation (ESI,† Section S3) showed the
samples (named DCA@Zr-LX) to be crystalline, porous, and
contain significant quantities of DCA at defect sites, albeit in
lower quantities than the smaller particles. Defect loading of
drugs offers potential slow release of molecules bonded to the
Zr6 SBUs while maintaining both porosity, for introduction of
further drugs, and stability, to allow subsequent postsynthetic
functionalisation.9
Incorporation of modulators with low pKa values into Zr
MOFs is known to induce higher surface charge and thus
enhance dispersion in water.15 Dynamic light scattering (DLS,
Section S4, ESI†) measurements (0.1 mg mL1 in water) showed
some aggregation of the smaller samples; DCA@Zr-L1small,
DCA@Zr-L2small and DCA@Zr-L3small form stable aggregates
ofB250 nm, while the average size of DCA@Zr-L4small aggregates
isB75 nm, closer to the size determined by SEM. Positive surface
charge from the protonated amino units of L4 may decrease
aggregation. Of the larger particles, only DCA@Zr-L3 (B350 nm)
and DCA@Zr-L6 (B550 nm) show any notable deviation from the
SEM particle size analyses. Nanoparticles are known to be further
stabilised by the formation of a surface protein corona,8,16 hence,
when the smaller MOFs were dispersed in phosphate buﬀered
saline (pH = 7.4) spiked with 2% w/w bovine serum album, their
aggregation drastically decreased, with particle sizes close to the
Fig. 2 (a) Stacked PXRD patterns of DCA@MOFs. SEM images of (b) DCA@Zr-L1small (B20 nm) and (c) DCA@Zr-L5 (B230 nm). (d) N2 uptake isotherms
(77 K) of DCA@Zr-L1small and DCA@Zr-L5. Filled symbols represent adsorption, empty symbols desorption. (e) TGA traces of DCA@Zr-L1small and
DCA@Zr-L5 compared to pristine Zr-L1.
Table 1 Pertinent physical characteristics of the DCA@MOFs
Size/nm (SEM) % DCA w/w BET SA/m2 g1 Pore vol/cc g1 % 5-FUa w/w
DCA@Zr-L1small 12.8  3.6 26.2 891 0.87 1.9
DCA@Zr-L2small 30.2  7.9 19.3 639 0.81 3.8
DCA@Zr-L3small 21.7  5.3 21.5 901 1.12 4.3
DCA@Zr-L4small 12.5  2.9 26.4 990 1.21 2.4
DCA@Zr-L5 232  30 14.1 764 0.42 1.5
DCA@Zr-L6 196  32 6.6 2241 0.99 2.5
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ones determined by SEM for the positively charged DCA@
Zr-L4small and aggregates ofB100 nm for the rest of the smaller
MOFs. Aggregation of DCA@Zr-L6 (B200 nm) also decreased.
The cytotoxicity of the DCA@MOFs towards MCF-7 breast
cancer cells was assessed using the MTS cell proliferation assay
(ESI,† Section S5). Free DCA has little eﬀect on cell proliferation,
as its hydrophilic nature results in poor internalisation;17 a
decrease in cell viability was observed only for concentrations
43 mg mL1 (Fig. S28, ESI†). To examine the eﬀect of ligand
functionality, the cytotoxicities of the larger DCA-containing
terephthalate derivatives (ca. 70–130 nm) were compared with
DCA@Zr-L5 and DCA@Zr-L6 (ca. 200 nm), and plotted against
DCA concentration (Fig. 3a). DCA@Zr-L5 and DCA@Zr-L6 are
most therapeutically active, decreasing MCF-7 viabilities to around
35%when deliveringo0.1mgmL1 of DCA. These results correlate
well with the enhanced cytotoxicity towards HeLa cancer cells
of Zr-L6 when delivering the anti-cancer drug a-cyano-4-hydroxy-
cinnamic acid,8 likely as a consequence of the preference of
Zr-L5 and Zr-L6 for caveolae-mediated endocytosis promoting
efficient cytosolic cargo release,7 rather than size, as empty
Zr-L5 and Zr-L6 samples of varying size were found to not be
cytotoxic towards HeLa cells.8
DCA@Zr-L1, in contrast, shows no cytotoxicity towards MCF-7,
likely due to clathrin-mediated endocytosis leading to lysosome
localisation; our previous work showed that a similar material
has no cytotoxicity towards HeLa cells at similar concentrations.9
DCA@Zr-L2 and DCA@Zr-L3 only reduce proliferation to 61 
16% and 81  15%, respectively, at the highest delivered DCA
concentrations, while the enhanced therapeutic eﬀect of DCA@
Zr-L4, with cell viabilities similar to DCA@Zr-L5, could be a
result of the positive surface charge of protonated amino units
in L4 enhancing internalisation eﬃciency.18 The eﬀect of
particle size was assessed by comparing the cytotoxicities of the
DCA@Zr-LXsmall derivatives (B20 nm) towards MCF-7 cells with
their larger DCA@Zr-LX analogues (B100 nm), and generally the
smaller nanoparticles showed enhanced cytotoxicity when
plotted against DCA concentration, suggesting enhanced inter-
nalisation and cell uptake by passive diﬀusion resulting in
cytosolic release.18b Fig. 3b shows the more pronounced cyto-
toxicity of DCA@Zr-L3small compared to its larger analogue,
which shows no appreciable deleterious eﬀects, with similar
trends observed for DCA@Zr-L1small and DCA@Zr-L2small
(Fig. S31, ESI†). Only DCA@Zr-L4small (ca. 13 nm) was less
eﬃcient than its larger analogue DCA@Zr-L4 (ca. 86 nm), but
both samples still reduced cell proliferation, again likely due to
their surfaces having significant positive charge.
It has been reported that DCA enhances the cytotoxic activity
of anticancer drugs such as 5-fluorouracil (5-FU) while reducing
cancer cells’ resistance towards them.17b,19 As such, the smaller,
DCA-loaded terephthalate MOF samples that had shown generally
enhanced cytotoxicity, along with DCA@Zr-L5 and DCA@Zr-L6,
were postsynthetically loaded with 5-FU to generate multimodal
DDSs (ESI,† Section S6). Thermogravimetric analysis cannot
distinguish between loaded DCA and 5-FU, although it suggests
some loss of DCA during 5-FU loading for the small terephthalate
MOFs. The loading of 5-FU, shown in Table 1, was calculated by
UV-Vis spectroscopy, and found to range from 1.5–4.3% w/w.
The enhanced cytotoxicity (ESI,† Section S7) of all the 5-FU@
DCA@MOFs towards MCF-7 cells compared to their DCA@
MOF precursors, despite the decrease in DCA content, is clearly
observed when cell proliferation is plotted against MOF concen-
tration (Fig. 4a) suggesting successful intracellular deliver of 5-FU.
Of the smaller MOF species, 5-FU@DCA@Zr-L1small exhibits a more
significant dose–response effect than its precursor, decreasing cell
viability with concentration down to 21 7% at 1 mg mL1. The
cytotoxicity of 5-FU@DCA@Zr-L2small increases only slightly
compared to its precursor, whereas 5-FU@DCA@Zr-L3small and
5-FU@DCA@Zr-L4small have more notable enhancements,
with cell viabilities of 19  7% and 33  8%, respectively, when
MCF-7 cells were incubated with 0.5 mg mL1 of the MOFs.
Fig. 3 (a) MCF-7 cell proliferation on incubation with the larger DCA@
MOFs. Exact cell viability values are tabulated in the supporting information
alongside plots against MOF concentration. (b) Comparison of MCF-7 cell
proliferation for smaller and larger DCA@Zr-L3 and DCA@Zr-L4 samples.
Fig. 4 (a) Comparison of MCF-7 cell proliferation on incubation with
DCA@MOFs versus 5-FU@DCA@MOFs. (b) Comparison of activities of
5-FU@DCA@MOFs plotted against 5-FU concentration. Exact cell viability
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The most effective of the DCA@MOFs also showed further
enhancements in cytotoxicity towards MCF-7 cells when loaded
with 5-FU; cell viability drastically decreases to values of 7  6%
and 4  6% when cells were incubated with just 0.5 mg mL1 of
5-FU@DCA@Zr-L5 and 5-FU@DCA@Zr-L6, respectively.
Free 5-FU itself also has significant dose-responsive cytotoxic
behaviour (Fig. 4b), with an IC50 of 0.015  0.001 mg mL1, but
plotting cytotoxicity of the 5-FU@DCA@MOF samples against
5-FU concentration shows they have a greater eﬀect than the free
drug at lower concentrations, which might be a consequence of
more eﬃcient or faster internalisation, or a synergistic eﬀect of
DCA and 5-FU delivered in tandem, given that the cytotoxicity
of free 5-FU is not enhanced when administered with DCA
(Fig. S36, ESI†). At higher concentrations 5-FU@DCA@Zr-L1small
and 5-FU@DCA@Zr-L4small continue to exhibit greater cytotoxic
eﬀects than the free drug, while 5-FU@DCA@Zr-L3small has
no notable enhancement and 5-FU@DCA@Zr-L2small has a
poorer performance than free 5-FU. Again, the larger samples,
5-FU@DCA@Zr-L5 and 5-FU@DCA@Zr-L6 have the most pro-
nounced cytotoxic eﬀects, significantly enhancing the eﬃcacy of
free 5-FU and killing nearly all cells at all measured concentrations,
suggesting that it is the surface chemistry of the MOFs that
influences cellular uptake, and thus cytotoxicity, to a greater extent.
We have shown that incorporation of DCA at defect sites
during the modulated synthesis of Zr MOFs oﬀers (i) particle
size control in the assembly of highly defective B20 nm
nanoparticles of hierarchically porous materials, (ii) high loading
(15–25% w/w) of the anticancer probe molecule DCA, and (iii)
porous MOFs into which further medicinal cargo can be loaded.
On the whole, the smaller (B20 nm) DCA-loaded particles exhibit
greater cytotoxicity towards MCF-7 cancer cells than their larger
(B100 nm) analogues; we hypothesise that partial internalisation
of the smaller MOFs through passive diffusion allows DCA
release directly into the cytosol to enhance its therapeutic effects.
However, the surface chemistry of the MOFs has a greater effect,
with DCA@Zr-L5 and DCA@Zr-L6 the most therapeutically
efficient MOFs, despite their bigger size, in agreement with
our recent study on endocytosis mechanisms.7 Concurrent
delivery of two drugs from the 5-FU@DCA@MOFs further
enhances cytotoxicity compared to precursor DCA@MOFs and
the free drugs. Delivery of multiple drugs from one DDS has the
potential to overcome issues with resistance and poor efficacy,
and is enabled by utilisation of different loading protocols;
defect-loading of cargo into Zr MOFs is possible for any
carboxylic acid containing drug.
RSF thanks the Royal Society for a URF and the University of
Glasgow for funding.
Conflicts of interest
There are no conflicts to declare.
Notes and references
1 (a) T.-G. Iversen, T. Skotland and K. Sandvig,Nano Today, 2011, 6, 176–185;
(b) I. Canton and G. Battaglia, Chem. Soc. Rev., 2012, 41, 2718–2739.
2 L. Treuel, X. Jiang and G. U. Nienhaus, J. R. Soc., Interface, 2013,
10, 20120939.
3 H. Furukawa, K. E. Cordova, M. O’Keeﬀe and O. M. Yaghi, Science,
2013, 341, 1230444.
4 P. Horcajada, R. Gref, T. Baati, P. K. Allan, G. Maurin, P. Couvreur,
G. Fe´rey, R. E. Morris and C. Serre, Chem. Rev., 2012, 112, 1232–1268.
5 (a) J. H. Cavka, S. Jakobsen, U. Olsbye, N. Guillou, C. Lamberti,
S. Bordiga and K. P. Lillerud, J. Am. Chem. Soc., 2008, 130,
13850–13851; (b) Y. Bai, Y. Dou, L.-H. Xie, W. Rutledge, J.-R. Li
and H.-C. Zhou, Chem. Soc. Rev., 2016, 45, 2327–2367.
6 (a) X. Zhu, J. Gu, Y. Wang, B. Li, Y. Li, W. Zhao and J. Shi, Chem.
Commun., 2014, 50, 8779–8782; (b) C. He, K. Lu, D. Liu andW. Lin, J. Am.
Chem. Soc., 2014, 136, 5181–5184; (c) D. Chen, D. Yang, C. A. Dougherty,
W. Lu, H.Wu, X. He, T. Cai, M. E. Van Dort, B. D. Ross andH. Hong, ACS
Nano, 2017, 11, 4315–4327; (d) R. Ro¨der, T. Preiß, P. Hirschle,
B. Steinborn, A. Zimpel, M. Ho¨hn, J. O. Ra¨dler, T. Bein, E. Wagner,
S. Wuttke and U. La¨chelt, J. Am. Chem. Soc., 2017, 139, 2359–2368;
(e) M. H. Teplensky, M. Fantham, P. Li, T. C. Wang, J. P. Mehta,
L. J. Young, P. Z. Moghadam, J. T. Hupp, O. K. Farha, C. F. Kaminski
and D. Fairen-Jimenez, J. Am. Chem. Soc., 2017, 139, 7522–7532.
7 C. Orellana-Tavra, S. Haddad, R. J. Marshall, I. Aba´nades La´zaro,
G. Boix, I. Imaz, D. Maspoch, R. S. Forgan and D. Fairen-Jimenez,
ACS Appl. Mater. Interfaces, 2017, 9, 35516–35525.
8 C. Orellana-Tavra, R. J. Marshall, E. F. Baxter, I. A. Lazaro, A. Tao,
A. K. Cheetham, R. S. Forgan and D. Fairen-Jimenez, J. Mater. Chem. B,
2016, 4, 7697–7707.
9 I. Aba´nades La´zaro, S. Haddad, S. Sacca, C. Orellana-Tavra,
D. Fairen-Jimenez and R. S. Forgan, Chem, 2017, 2, 561–578.
10 (a) A. Schaate, P. Roy, A. Godt, J. Lippke, F. Waltz, M. Wiebcke and
P. Behrens, Chem. – Eur. J., 2011, 17, 6643–6651; (b) C. V. McGuire
and R. S. Forgan, Chem. Commun., 2015, 51, 5199–5217.
11 (a) E. D. Michelakis, L. Webster and J. R. Mackey, Br. J. Cancer, 2008, 99,
989–994; (b) E. D. Michelakis, G. Sutendra, P. Dromparis, L. Webster,
A. Haromy, E. Niven, C. Maguire, T. L. Gammer, J. R. Mackey, D. Fulton,
B. Abdulkarim, M. S. McMurtry and K. C. Petruk, Sci. Transl. Med., 2010,
2, 31ra34; (c) D. Heshe, S. Hoogestraat, C. Brauckmann, U. Karst, J. Boos
and C. Lanvers-Kaminsky, Cancer Chemother. Pharmacol., 2011, 67,
647–655.
12 (a) M. Taddei, K. C. Dumbgen, J. A. van Bokhoven and M. Ranocchiari,
Chem. Commun., 2016, 52, 6411–6414; (b) B. Bueken, N. Van Velthoven,
T. Willhammar, T. Stassin, I. Stassen, D. A. Keen, G. V. Baron,
J. F. M. Denayer, R. Ameloot, S. Bals, D. De Vos and T. D. Bennett, Chem.
Sci., 2017, 8, 3939–3948.
13 V. Bon, I. Senkovska, M. S. Weiss and S. Kaskel, CrystEngComm,
2013, 15, 9572–9577.
14 F. Rouquerol, J. Rouquerol and K. Sing, in Adsorption by Powders and
Porous Solids, Academic Press, London, 1999, 191–217.
15 W. Morris, S. Wang, D. Cho, E. Auyeung, P. Li, O. K. Farha and
C. A. Mirkin, ACS Appl. Mater. Interfaces, 2017, 9, 33413–33418.
16 (a) E. Bellido,M. Guillevic, T. Hidalgo, M. J. Santander-Ortega, C. Serre and
P. Horcajada, Langmuir, 2014, 30, 5911–5920; (b) E. Bellido, T. Hidalgo,
M. V. Lozano, M. Guillevic, R. Simo´n-Va´zquez, M. J. Santander-Ortega,
A´. Gonza´lez-Ferna´ndez, C. Serre, M. J. Alonso and P. Horcajada, Adv.
Healthcare Mater., 2015, 4, 1246–1257.
17 (a) C. Trapella, R. Voltan, E. Melloni, V. Tisato, C. Celeghini, S. Bianco,
A. Fantinati, S. Salvadori, R. Guerrini, P. Secchiero and G. Zauli, J. Med.
Chem., 2016, 59, 147–156; (b) J. Zajac, H. Kostrhunova, V. Novohradsky,
O. Vrana, R. Raveendran, D. Gibson, J. Kasparkova and V. Brabec, J. Inorg.
Biochem., 2016, 156, 89–97.
18 (a) A. M. Bannunah, D. Vllasaliu, J. Lord and S. Stolnik, Mol.
Pharmaceutics, 2014, 11, 4363–4373; (b) K. Yin Win and S.-S. Feng,
Biomaterials, 2005, 26, 2713–2722.
19 Y. Xuan, H. Hur, I.-H. Ham, J. Yun, J.-Y. Lee, W. Shim, Y. B. Kim,
G. Lee, S.-U. Han and Y. K. Cho, Exp. Cell Res., 2014, 321, 219–230.
Communication ChemComm
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
2 
Fe
br
ua
ry
 2
01
8.
 D
ow
nl
oa
de
d 
on
 1
9/
03
/2
01
8 
18
:4
0:
47
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
